Skip to content
Back to SI

Shoulder Innovations, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
24
Purchases
7
Sales
17
Purchase value
$214.87K
Sale value
$5.47M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Robert Joseph BallDirector · CEO & Executive Chairman
4
Filed Sep 14, 2026Period of report Sep 14, 20260002070664-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 14, 2026
Common StockF210,175$18.4478$187.71K380,824Direct
Filing footnotes · 3
  1. F1Includes 1,748 shares of Common Stock acquired on June 30, 2026 pursuant to the Issuer's 2025 Employee Stock Purchase Plan.
  2. F2The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $18.22 to $18.63, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein. The shares of Common Stock were sold solely to cover the exercise price in connection with the exercise of the stock option.
  3. F3The stock option is fully vested and currently exercisable.
Open on SEC EDGAR
Gilde Healthcare Holding B.V.10% owner
4
Filed Aug 28, 2026Period of report Aug 26, 20260001193125-26-374359
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 26, 2026
Common StockF11,196$22.60$27.03K2,185,914IndirectSee footnote
Filing footnotes · 1
  1. F1Held directly by Cooperatieve Gilde Healthcare V U.A. ("Gilde"). Gilde Healthcare V Management B.V. is the managing director of Gilde and has sole voting and dispositive power with respect to the shares held by Gilde. Gilde Healthcare V Management B.V. is owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director). Geoff Pardo is a partner at Gilde and may be deemed to share voting and dispositive power with respect to the shares held of record by Gilde. Mr. Pardo disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.
Open on SEC EDGAR
Gilde Healthcare Holding B.V.10% owner
4
Filed Aug 24, 2026Period of report Aug 20, 20260001193125-26-363913
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 24, 2026
Common StockF3F1681$22.62$15.40K2,187,110IndirectSee footnote
SaleAug 21, 2026
Common StockF2F120,516$22.61$463.87K2,187,791IndirectSee footnote
SaleAug 20, 2026
Common StockF13,900$22.60$88.14K2,208,307IndirectSee footnote
Filing footnotes · 3
  1. F1Held directly by Cooperatieve Gilde Healthcare V U.A. ("Gilde"). Gilde Healthcare V Management B.V. is the managing director of Gilde and has sole voting and dispositive power with respect to the shares held by Gilde. Gilde Healthcare V Management B.V. is owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director). Geoff Pardo is a partner at Gilde and may be deemed to share voting and dispositive power with respect to the shares held of record by Gilde. Mr. Pardo disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.
  2. F2This figure is the weighted average sales price of multiple trades ranging from $22.60 to $22.67 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, Shoulder Innovations, Inc. or any security holder of Shoulder Innovations, Inc. full information about the number of shares sold at each separate price upon request.
  3. F3This figure is the weighted average sales price of multiple trades ranging from $22.60 to $22.78 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, Shoulder Innovations, Inc. or any security holder of Shoulder Innovations, Inc. full information about the number of shares sold at each separate price upon request.
Open on SEC EDGAR
Matthew Fraser AhearnDirector · Chief Operating Officer
4Rule 10b5-1 plan disclosed
Filed Aug 18, 2026Period of report Aug 14, 20260002070582-26-000005
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 18, 2026
Common StockF1F312,586$20.9354$263.49K245,776Direct
SaleAug 18, 2026
Common StockF1F41,600$21.3819$34.21K244,176Direct
SaleAug 17, 2026
Common StockF1F28,314$20.0988$167.10K258,362Direct
Filing footnotes · 4
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
  2. F2The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $20.00 to $20.525, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.
  3. F3The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $20.25 to $21.24, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.
  4. F4The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $21.25 to $21.46, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.
Open on SEC EDGAR
Gilde Healthcare Holding B.V.10% owner
4
Filed Aug 7, 2026Period of report Aug 5, 20260001193125-26-340260
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 6, 2026
Common StockF22,095$22.60$47.35K2,212,207IndirectSee footnote
SaleAug 5, 2026
Common StockF1F27,338$22.64$166.13K2,214,302IndirectSee footnote
Filing footnotes · 2
  1. F1This figure is the weighted average sales price of multiple trades ranging from $22.60 to $23.00 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, Shoulder Innovations, Inc. or any security holder of Shoulder Innovations, Inc. full information about the number of shares sold at each separate price upon request.
  2. F2Held directly by Cooperatieve Gilde Healthcare V U.A. ("Gilde"). Gilde Healthcare V Management B.V. is the managing director of Gilde and has sole voting and dispositive power with respect to the shares held by Gilde. Gilde Healthcare V Management B.V. is owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director). Geoff Pardo is a partner at Gilde and may be deemed to share voting and dispositive power with respect to the shares held of record by Gilde. Mr. Pardo disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.
Open on SEC EDGAR
Gilde Healthcare Holding B.V.10% owner
4
Filed Aug 5, 2026Period of report Aug 3, 20260001193125-26-335278
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 4, 2026
Common StockF3F299,812$22.77$2.27M2,221,640IndirectSee footnote
SaleAug 3, 2026
Common StockF1F210,751$22.71$244.16K2,321,452IndirectSee footnote
Filing footnotes · 3
  1. F1This figure is the weighted average sales price of multiple trades ranging from $22.60 to $23.05 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, Shoulder Innovations, Inc. or any security holder of Shoulder Innovations, Inc. full information about the number of shares sold at each separate price upon request.
  2. F2Held directly by Cooperatieve Gilde Healthcare V U.A. ("Gilde"). Gilde Healthcare V Management B.V. is the managing director of Gilde and has sole voting and dispositive power with respect to the shares held by Gilde. Gilde Healthcare V Management B.V. is owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director). Geoff Pardo is a partner at Gilde and may be deemed to share voting and dispositive power with respect to the shares held of record by Gilde. Mr. Pardo disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.
  3. F3This figure is the weighted average sales price of multiple trades ranging from $22.60 to $23.04 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, Shoulder Innovations, Inc. or any security holder of Shoulder Innovations, Inc. full information about the number of shares sold at each separate price upon request.
Open on SEC EDGAR
Gilde Healthcare Holding B.V.10% owner
4
Filed Aug 3, 2026Period of report Jul 30, 20260001193125-26-330846
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 31, 2026
Common StockF3F220,034$22.73$455.37K2,332,203IndirectSee Footnote
SaleJul 30, 2026
Common StockF1F228,245$23.36$659.80K2,352,237IndirectSee Footnote
Filing footnotes · 3
  1. F1This figure is the weighted average sales price of multiple trades ranging from $23.00 to $23.73 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, Shoulder Innovations, Inc. or any security holder of Shoulder Innovations, Inc. full information about the number of shares sold at each separate price upon request.
  2. F2Held directly by Cooperatieve Gilde Healthcare V U.A. ("Gilde"). Gilde Healthcare V Management B.V. is the managing director of Gilde and has sole voting and dispositive power with respect to the shares held by Gilde. Gilde Healthcare V Management B.V. is owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director). Geoff Pardo is a partner at Gilde and may be deemed to share voting and dispositive power with respect to the shares held of record by Gilde. Mr. Pardo disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.
  3. F3This figure is the weighted average sales price of multiple trades ranging from $22.60 to $23.00 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, Shoulder Innovations, Inc. or any security holder of Shoulder Innovations, Inc. full information about the number of shares sold at each separate price upon request.
Open on SEC EDGAR
Matthew Fraser AhearnDirector · Chief Operating Officer
4Rule 10b5-1 plan disclosed
Filed Jun 16, 2026Period of report Jun 12, 20260002070582-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 15, 2026
Common StockF1F41,644$18.2005$29.92K271,676Direct
SaleJun 15, 2026
Common StockF1F52,500$19.2592$48.15K269,176Direct
SaleJun 12, 2026
Common StockF1F2F315,856$18.6797$296.19K273,320Direct
Filing footnotes · 5
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
  2. F2The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $18.29 to $19.00, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.
  3. F3Includes the following shares received without consideration as an in-kind distribution: 2,411 shares from Genesis Investment Holdings. In prior reports, the reporting person reported beneficial ownership of 286,765 shares of Shoulder Innovations common stock held directly.
  4. F4The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $17.98 to $18.88, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.
  5. F5The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $18.98 to $19.71, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.
Open on SEC EDGAR
Robert Joseph BallDirector · CEO & Executive Chairman
4
Filed Mar 17, 2026Period of report Mar 13, 20260002070664-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMar 13, 2026
Common StockF12,200$15.1782$33.39K278,866Direct
Filing footnotes · 1
  1. F1The price reported in Column 4 is a weighted average purchase price. The shares of Common Stock were purchased in multiple transactions at prices ranging from $14.80 to $15.50, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock purchased at each separate price within the range set forth herein.
Open on SEC EDGAR
Richard BuchholzDirector
4
Filed Mar 17, 2026Period of report Mar 13, 20260001737133-26-000001
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMar 13, 2026
Common Stock1,000$14.84$14.84K13,666Direct
Open on SEC EDGAR
Jeffrey S. PointsChief Financial Officer
4
Filed Mar 17, 2026Period of report Mar 13, 20260001731414-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMar 13, 2026
Common Stock2,000$15.00$30.00K70,785Direct
Filing footnotes · 1
  1. F1The stock option vests in 31 equal increments on the last day of each calendar month beginning on March 31, 2025.
Open on SEC EDGAR
Jeffrey S. PointsChief Financial Officer
4
Filed Dec 15, 2025Period of report Dec 11, 20250001628280-25-057080
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseDec 12, 2025
Common Stock1,005$14.98$15.05K54,445Direct
PurchaseDec 11, 2025
Common Stock995$14.65$14.58K53,440Direct
Open on SEC EDGAR
Robert Joseph BallDirector · CEO & Executive Chairman
4
Filed Dec 15, 2025Period of report Dec 11, 20250001628280-25-057067
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseDec 12, 2025
Common StockF23,900$14.8911$58.08K118,457Direct
PurchaseDec 11, 2025
Common StockF13,300$14.8285$48.93K114,557Direct
Filing footnotes · 2
  1. F1The price reported in Column 4 is a weighted average purchase price. The shares of Common Stock were purchased in multiple transactions at prices ranging from $14.56 to $15.16, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock purchased at each separate price within the range set forth herein.
  2. F2The price reported in Column 4 is a weighted average purchase price. The shares of Common Stock were purchased in multiple transactions at prices ranging from $14.60 to $15.26, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock purchased at each separate price within the range set forth herein.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.